Eikon Therapeutics Reports Third Quarter 2026 Financial Results
Eikon Therapeutics, Inc. (EIKN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates • Presented seven posters at the 2026 European Society for Medical Oncology (ESMO) Congress highlighting progress across the oncology portfolio, including clinical data from
How this was made
The 30-second read
Why it matters
The disclosed trial outcomes provide fresh efficacy metrics that could shift market expectations for upcoming regulatory filings and future financing.
Market read
Positive trial data may prompt short‑term buying pressure in EIKN and influence peer biotech valuations.
What to watch
Cash runway of $461.7 M may limit future trial funding without additional capital raises.
Eikon reports Q3 2026 net loss of $86.1 million as R&D expense rises 21%; cash of $461.7 million supports runway into Q1 2028
The release reports no revenue. Operating expenses and net loss both widened year over year, with R&D up 21% for the quarter. Offsetting this, the company reports $461.7 million in cash, a runway guidance extension into Q1 2028, and several clinical and regulatory milestones, including an IND submission for EIK1006.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expenses, three months ended Sept 30, 2026GAAP | $71.83M | – | increase of $12.5 million, or 21% |
| General and administrative expenses, three months ended Sept 30, 2026GAAP | $18.73M | – | increase of $3.3 million, or 21% |
| Total operating expenses, three months ended Sept 30, 2026GAAP | $90.55M | – | – |
| Loss from operations, three months ended Sept 30, 2026GAAP | −$90.55M | – | – |
| Interest income (expense), net, three months ended Sept 30, 2026GAAP | $4.49M | – | – |
| Other income (expense), net, three months ended Sept 30, 2026GAAP | −$46K | – | – |
| Net loss and comprehensive loss, three months ended Sept 30, 2026GAAP | −$86.11M | – | – |
| Net loss attributable to common stockholders, three months ended Sept 30, 2026GAAP | $86.1 million net loss | – | – |
| Net loss per share attributable to common stockholders, basic and diluted, three months ended Sept 30, 2026GAAP | $(1.59) | – | – |
| Research and development expenses, nine months ended Sept 30, 2026GAAP | $217.3M | – | – |
| General and administrative expenses, nine months ended Sept 30, 2026GAAP | $53.95M | – | down 24% |
| Total operating expenses, nine months ended Sept 30, 2026GAAP | $271.3M | – | increased 6% |
| Loss from operations, nine months ended Sept 30, 2026GAAP | −$271.3M | – | – |
| Interest income (expense), net, nine months ended Sept 30, 2026GAAP | $13.90M | – | – |
| Other income (expense), net, nine months ended Sept 30, 2026GAAP | −$99K | – | – |
| Net loss and comprehensive loss, nine months ended Sept 30, 2026GAAP | −$257.5M | – | – |
| Impact of preferred stock extinguishments and modifications, nine months ended Sept 30, 2025GAAP | −$9.40M | – | – |
| Net loss attributable to common stockholders, nine months ended Sept 30, 2026GAAP | −$257.5M | – | – |
| Net loss per share attributable to common stockholders, basic and diluted, nine months ended Sept 30, 2026GAAP | $(5.43) | – | – |
| Cash, cash equivalents and marketable securities, as of Sept 30, 2026other | $461.7M | – | – |
| Total assets, as of Sept 30, 2026other | $706.2M | – | – |
| Total liabilities, as of Sept 30, 2026other | $321.9M | – | – |
| Total stockholders' equity (deficit), as of Sept 30, 2026other | $384.3M | – | – |
| Net cash used in operating activities, nine months ended Sept 30, 2026other | $224M | – | – |
Capital returns
- The filing reports no share repurchases and no dividends for the period.
What drove it
- R&D expenses rose $12.5 million, or 21%, to $71.8 million. The company states that direct R&D expenses increased $9.2 million as it advanced its clinical trial activity, and compensation costs increased $3.0 million.
- G&A expenses rose $3.3 million, or 21%, to $18.7 million. The company states this was primarily due to $1.5 million higher professional fees from consulting and legal expenses and $1.1 million higher other operating expenses, primarily IT expenses.
- For the nine months, the CFO states total operating expenses increased 6% year over year, G&A decreased 24%, and R&D represented 80% of the total.
- Clinical activity in the period included EIK1001 data at ESMO (TeLuRide-005, pooled ORR 63.1%, n=65), first patient dosed in TeLuRide-008 (July 27, 2026), EIK1003 and EIK1004 Phase 1/2 data at ESMO, EIK1005 preliminary data, and an IND submitted for EIK1006 (Oct 14, 2026).
- The company states that it is concentrating investment behind its most advanced programs and tying incremental spending to clinical milestones.
Concerns
- Net loss attributable to common stockholders widened to $86.1 million from $71.1 million in the prior-year quarter.
- Operating expenses rose in both the quarter and the nine months, with R&D up 21% in the quarter.
- Net cash used in operating activities was $224.0 million over nine months, against $461.7 million of cash at quarter end.
- The release reports no revenue line and no numeric financial guidance, so the runway statement is the only forward financial figure.
- Several efficacy results cited are from small cohorts and single-arm settings, for example EIK1003 monotherapy ORR of 14.3% across 49 efficacy-evaluable participants and EIK1005 preliminary data from a limited number of participants.
What to watch
- Interim analysis for advancement to Phase 3 in TeLuRide-006 (EIK1001 in advanced melanoma), anticipated in the first half of 2027.
- Interim analysis for dose selection in TeLuRide-008, anticipated in the second half of 2027.
- Additional EIK1005 results from the combination study with pembrolizumab, expected in the first half of 2027.
- Initial EIK1003 Cohort 1D results with paclitaxel and platinum-based chemotherapy, expected in the second half of 2027.
- Initial results from the EIK1004 combination arm with docetaxel in castrate-resistant prostate cancer, expected in the second half of 2027.
- Preliminary EIK1006 safety and efficacy data, expected in the second half of 2027, subject to FDA clearance to start the Phase 1/2 study.
- Whether cash of $461.7 million continues to support operations into Q1 2028 as operating spend rises.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities were $461,717 thousand at Sept 30, 2026, compared with $335,975 thousand at Dec 31, 2025.
- Total assets were $706,201 thousand at Sept 30, 2026, compared with $594,734 thousand at Dec 31, 2025.
- Total liabilities were $321,908 thousand at Sept 30, 2026, compared with $312,298 thousand at Dec 31, 2025.
- Total stockholders' equity was $384,293 thousand at Sept 30, 2026, compared with a deficit of $(879,034) thousand at Dec 31, 2025.
- Net cash used in operating activities was $224.0 million for the nine months ended Sept 30, 2026. The filing does not print the comparable prior-year figure.
- Eikon expects its current cash, cash equivalents, and marketable securities to fund operations into the first quarter of 2028.
Analysis
Eikon reported a third-quarter 2026 net loss attributable to common stockholders of $86.1 million, compared with $71.1 million in the prior-year quarter, and EPS of $(1.59) against $(24.24). The release contains no revenue line, so the read is driven entirely by expenses and the balance sheet. Total operating expenses for the quarter were $90,552 thousand, against $74,751 thousand a year earlier. R&D expense was $71,826 thousand, up 21%, and the company attributes the increase to advancing clinical trial activity and higher compensation costs. G&A expense was $18,726 thousand, up 21%, which the company attributes mainly to higher professional fees and IT expenses.
Over the nine months, the picture differs by line. Total operating expenses were $271,283 thousand, which the CFO describes as an increase of 6% year over year. G&A for the nine months was $53,950 thousand, which the CFO describes as down 24%, while R&D was $217,333 thousand. Interest income, net, was $4,486 thousand for the quarter and $13,903 thousand for the nine months, and it offset part of the operating loss in the net loss line. The filing prints no prior-quarter (June 30, 2026) figures, so sequential comparisons are not available from this document.
On the balance sheet, cash, cash equivalents and marketable securities were $461,717 thousand at September 30, 2026, up from $335,975 thousand at December 31, 2025. Stockholders' equity moved from a deficit of $(879,034) thousand to $384,293 thousand over the same span. The filing does not state the source of that change, so the reader should review the 10-Q for the cause. Net cash used in operating activities was $224.0 million for the nine months. Management updated runway guidance to fund operations into the first quarter of 2028.
Clinical disclosures are the bulk of the release. EIK1001 in TeLuRide-005 reported a pooled ORR of 63.1% and DCR of 89.2% across 65 efficacy-evaluable patients, with squamous and non-squamous cohorts reported separately. EIK1003 monotherapy reported an ORR of 14.3% across 49 participants, with 31.3% among PARP inhibitor-naive participants. EIK1004 reported an ORR of 12.1% across 58 participants. These are early and small-cohort data. The milestone calendar places multiple interim analyses in 2027, including the TeLuRide-006 Phase 3 advancement decision and the TeLuRide-008 dose-selection analysis.
The release provides no numeric financial guidance and no prior outlook to compare against, so the vs_prior_guidance list is empty. The only forward financial statement is the runway into the first quarter of 2028, and the filing does not print the prior runway date.
Management, verbatim
We ended the third quarter with $461.7 million in cash and are updating our runway guidance into the first quarter of 2028, through the key clinical milestones anticipated in 2027.
Freddie Bowie, Ph.D., Chief Financial Officer
We are concentrating investment behind our most advanced programs and tying incremental spending to clinical milestones, with the goal of creating long-term shareholder value.
Freddie Bowie, Ph.D., Chief Financial Officer
The third quarter was marked by important progress across Eikon's oncology programs.
Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair
Not in the filing
stated, not guessed- Revenue or collaboration revenue for the three and nine months: the filing prints no revenue line.
- Gross margin and cost of sales: not reported.
- Prior-quarter (June 30, 2026) figures for all income statement and balance sheet lines: not printed.
- Prior-year nine-month net cash used in operating activities: not printed.
- Three-month net cash used in operating activities: not printed.
- Prior-year cash balance at Sept 30, 2025: not printed (only the Dec 31, 2025 balance is given).
- Percentage change for the net loss lines: not printed.
- Percentage change for total operating expenses in the three-month period: not printed.
- Prior runway guidance date: not printed, so the change in runway cannot be measured.
- Source of the increase in stockholders' equity from deficit to positive equity: not stated in the release.
- Numeric financial guidance for 2026 or 2027: not provided.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Eikon Therapeutics (Nasdaq: EIKN) is a late‑stage clinical biopharma focused on oncology, reporting its Q3 2026 financials and trial updates via an SEC 8‑K filing.
Ticker impact
Eikon Therapeutics filed an 8‑K reporting Q3 2026 results with new Phase 2/3 trial data showing 63.1% ORR for EIK1001 in NSCLC.
likely upward pressure as investors price in encouraging efficacy signals
New efficacy data for a late‑stage oncology candidate typically drives short‑term buying in biotech stocks.
Market effects
strengthens the oncology biotech sector with fresh data on PARP1 and WRN inhibitors
minimal regional effect, primarily U.S. biotech investors
limited to global biotech and oncology research communities
Counterpoint
Data may not translate to survival benefit; investors could be cautious until Phase 3 results.
Key entities
- companyEikon Therapeutics
Nasdaq‑listed biotech reporting Q3 results and clinical updates.
- drug_candidateEIK1001
TLR 7/8 dual‑agonist in Phase 2/3 NSCLC trial.

